SPRB:NASDAQSpruce Biosciences, Inc. Analysis
Data as of 2026-08-31 - not real-time
$60.78
Latest Price
9/10Risk
Risk Level: High
Executive Summary
The moving-average structure behind Spruce Biosciences, Inc. is neutral at $60.78, with no clear ordering between short and long averages. Across the trailing 30 sessions it gained 39.6%. RSI sits at 68.0, which reads as approaching overbought, and MACD momentum is bullish. Recent trading has carved out support near $41.46 and resistance around $64.50.
Multiples put this in undervalued territory: 7.4 times earnings against the sector's 30.5. Consensus targets land 143.3% above where the shares trade now.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 59.8%, a beta of 3.62 and a maximum drawdown of 77.3%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to hold, carrying 3/10 conviction.
Multiples put this in undervalued territory: 7.4 times earnings against the sector's 30.5. Consensus targets land 143.3% above where the shares trade now.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 59.8%, a beta of 3.62 and a maximum drawdown of 77.3%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to hold, carrying 3/10 conviction.
Top Market Events
Updated Aug 12, 2026 0 SOUTH SAN FRANCISCO, Calif.SOUTH SAN FRANCISCO, Calif., August 12, 2026--Spruce Biosciences, Inc. Nasdaq: SPRB , a late-stage biopharmaceutical...Yahoo Finance19dCure Sanfilippo Foundation and National MPS Society Make $5.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Trading below the 200-day average of 64.90
- MACD momentum is positive
- 30-day price change of +39.6%
Medium Term
1–3 yearsNeutral
Model confidence: 2/10
Key Factors
- P/E of 7.4 versus sector average of 30.5
- Trading below the 200-day average of 64.90
- Analyst targets imply +143.3% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 7.4 versus sector average of 30.5
- Analyst targets imply +143.3% versus the current price
- Negative return on equity of -106.0%
Key Metrics & Analysis
Financial Health
P/E Ratio7.4
ROE-105.98%
ROA-40.03%
Debt/Equity9.16
P/B Ratio2.0
Op. Cash Flow$-42624000
Free Cash Flow$-20647500
Industry P/E30.5
Technical Analysis
TrendNeutral
RSI68.0
Support$41.46
Resistance$64.50
MA 20$52.06
MA 50$49.83
MA 200$64.90
MACDBullish
VolumeIncreasing
Fear & Greed Index94.09
Valuation
Target Price$147.88
Upside/Downside143.30%
GradeUndervalued
TypeBlend
Risk Assessment
Beta3.62
Volatility59.82%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.